Cover Image
Market Research Report

Europe Dry Eye Syndrome Market: Industry Trends and Forecast to 2026

Published by Data Bridge Market Research Private Limited Product code 904458
Published Content info 220 Pages
Delivery time: 1-2 business days
Price
Back to Top
Europe Dry Eye Syndrome Market: Industry Trends and Forecast to 2026
Published: July 1, 2019 Content info: 220 Pages
Description

Europe dry eye syndrome treatment market is projected to register a substantial CAGR of in the forecast period 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Product Type (Tear stimulators, Artificial tears, Secretagogue, Others), Dosage Type ( Liquid, Semi-solid, Others), Drug Class( Lubricating Agents, Cholinergics, Anti-Inflammatory, Anti-Infectives, Anti-Allergics, Others), Dose(Unit dose, Multi-dose), Medication Type (Prescription (Rx) Drugs, Over The Counter (OTC) Drugs), Container Type (Unit-Dose Vials, Bottles, Tubes), Packaging Type (Plastic, Aluminium, Glass), Type (Brands, Generics), End Users (Home Healthcare, Hospitals, Clinics, Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Rest of Europe).

Some of the major factors contributing to the growth of the Europe dry eye syndrome treatment market:

  • Increasing research and development
  • Changing demographical trends to drive the market

Market Players:

The key market players for Europe dry eye syndrome treatment market are listed below:

  • ALLERGAN
  • Bausch & Lomb Incorporated
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Prestige Consumer Healthcare, Inc.
  • AKORN, INC.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novaliq GmbH
  • Santen Pharmaceutical Co., Ltd.,
  • Cardinal Health
  • Alembic Pharmaceuticals Limited.
  • Cipla Inc.
  • Perrigo Company plc
  • SENJU PHARMACEUTICAL CO. LTD.
  • Horus Pharma
  • ROHTO Pharmaceutical Co., Ltd.
  • VISUfarma
  • Hubrx
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF EUROPE DRY EYE SYNDROME MARKET
  • 1.4 CURRENCY AND PRICING
  • 1.5 LIMITATIONS
  • 1.6 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 EUROPE DRY EYE SYNDROME MARKET: GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR VENDOR SHARE ANALYSIS
  • 2.9 MULTIVARIATE MODELING
  • 2.10 PRODUCTS LIFELINE CURVE
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING PREVALENCE OF DRY EYE DISEASES
    • 3.1.2 CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET
    • 3.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
    • 3.1.4 RISING GERIATRIC POPULATION ACROSS THE WORLD
    • 3.1.5 INCREASE IN LASIK SURGERY AND USAGE OF CONTACT LENSES
  • 3.2 RESTRAINTS
    • 3.2.1 STRINGENT REGULATORY PROCESS
    • 3.2.2 UNMET MEDICAL NEEDS
  • 3.3 OPPORTUNITIES
    • 3.3.1 EMERGING MARKET PRESENTS SIGNIFICANT OPPORTUNITIES
    • 3.3.2 DEVELOPMENT OF NOVEL TECHNOLOGIES
  • 3.4 CHALLENGE
    • 3.4.1 INCREASING NUMBER OF PLAYERS

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE ANALYSIS

  • 6.1 OVERVIEW
  • 6.2 MARKETED DRUGS
  • 6.3 APPROVED/FILED DRUGS
  • 6.4 PHASE III TRIAL CANDIDATES
  • 6.5 PHASE II TRIAL CANDIDATES
  • 6.6 PHASE I TRIAL CANDIDATES
  • 6.7 OTHERS

7 EUROPE DRY EYE SYNDROME MARKET, BY PRODUCT TYPE

  • 7.1 OVERVIEW
  • 7.2 TEAR STIMULATORS
    • 7.2.1 PILOCARPINE
    • 7.2.2 CYCLOSPORINE
    • 7.2.3 LIFITEGRAST
  • 7.3 ARTIFICIAL TEARS
    • 7.3.1 SECRETAGOGUE
    • 7.3.2 OTHERS

8 EUROPE DRY EYE SYNDROME MARKET, BY DOSAGE TYPE

  • 8.1 OVERVIEW
  • 8.2 LIQUID
    • 8.2.1 SOLUTIONS
    • 8.2.2 EMULSIONS
    • 8.2.3 SUSPENSIONS
  • 8.3 SEMI-SOLID
    • 8.3.1 GEL
    • 8.3.2 OINTMENT
  • 8.4 OTHERS

9 EUROPE DRY EYE SYNDROME MARKET, BY DRUG CLASS

  • 9.1 OVERVIEW
  • 9.2 ANTI-INFLAMMATORY
  • 9.3 LUBRICATING AGENT
  • 9.4 ANTI-INFECTIVE
  • 9.5 ANTI-ALLERGIC
  • 9.6 CHOLINERGIC
  • 9.7 OTHERS

10 EUROPE DRY EYE SYNDROME MARKET, BY DOSE

  • 10.1 OVERVIEW
  • 10.2 MULTI DOSE
  • 10.3 UNIT DOSE

11 EUROPE DRY EYE SYNDROME MARKET, BY MEDICATION TYPE

  • 11.1 OVERVIEW
  • 11.2 PRESCRIPTION (RX) DRUGS
  • 11.3 OVER THE COUNTER (OTC) DRUGS

12 EUROPE DRY EYE SYNDROME MARKET, BY CONTAINER TYPE

  • 12.1 OVERVIEW
  • 12.2 UNIT DOSE VIALS
  • 12.3 BOTTLES
  • 12.4 TUBES

13 EUROPE DRY EYE SYNDROME MARKET, BY PACKAGING TYPE

  • 13.1 OVERVIEW
  • 13.2 PLASTIC
  • 13.3 GLASS
  • 13.4 ALUMINIUM

14 EUROPE DRY EYE SYNDROME MARKET, BY TYPE

  • 14.1 OVERVIEW
  • 14.2 GENERIC DRUG
  • 14.3 BRANDED
    • 14.3.1 RESTASIS
    • 14.3.2 XIIDRA
    • 14.3.3 REFRESH
    • 14.3.4 SYSTANE
    • 14.3.5 TEARS NATURALE
    • 14.3.6 IKERVIS
    • 14.3.7 DIQUAS
    • 14.3.8 OTHERS

15 EUROPE DRY EYE SYNDROME MARKET, BY END USER

  • 15.1 OVERVIEW
  • 15.2 HOME HEALTHCARE
  • 15.3 HOSPITALS
  • 15.4 CLINICS
  • 15.5 OTHERS

16 EUROPE DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL

  • 16.1 OVERVIEW
  • 16.2 HOSPITAL PHARMACIES
  • 16.3 RETAIL PHARMACIES
  • 16.4 ONLINE PHARMACIES
  • 16.5 OTHERS

17 EUROPE DRY EYE SYNDROME MARKET BY GEOGRAPHY

  • 17.1 EUROPE
    • 17.1.1 GERMANY
    • 17.1.2 U.K.
    • 17.1.3 FRANCE
    • 17.1.4 ITALY
    • 17.1.5 SPAIN
    • 17.1.6 RUSSIA
    • 17.1.7 NETHERLANDS
    • 17.1.8 SWITZERLAND
    • 17.1.9 BELGIUM
    • 17.1.10 TURKEY
    • 17.1.11 REST OF EUROPE

18 EUROPE DRY EYE SYNDROME MARKET, COMPANY LANDSCAPE

  • 18.1 COMPANY SHARE ANALYSIS: EUROPE

19 SWOT ANALYSIS

  • 19.1 DATA BRIDGE MARKET RESEARCH ANALYSIS-

20 COMPANY PROFILE

  • 20.1 ALLERGAN
    • 20.1.1 COMPANY SNAPSHOT
    • 20.1.2 REVENUE ANALYSIS
    • 20.1.3 COMPANY SHARE ANALYSIS
    • 20.1.4 GEOGRAPHICAL PRESENCE
    • 20.1.5 PRODUCT PORTFOLIO
    • 20.1.6 RECENT DEVELOPMENTS
  • 20.2 NOVARTIS AG
    • 20.2.1 COMPANY OVERVIEW
    • 20.2.2 REVENUE ANALYSIS
    • 20.2.3 COMPANY SHARE ANALYSIS
    • 20.2.4 GEOGRAPHICAL PRESENCE
    • 20.2.5 PRODUCT PORTFOLIO
    • 20.2.6 RECENT DEVELOPMENT
  • 20.3 BAUSCH & LOMB INCORPORATED.
    • 20.3.1 COMPANY SNAPSHOT
    • 20.3.2 REVENUE ANALYSIS
    • 20.3.3 COMPANY SHARE ANALYSIS
    • 20.3.4 GEOGRAPHICAL PRESENCE
    • 20.3.5 PRODUCT PORTFOLIO
    • 20.3.6 RECENT DEVELOPMENT
  • 20.4 SANTEN PHARMACEUTICAL CO., LTD.
    • 20.4.1 COMPANY OVERVIEW
    • 20.4.2 REVENUE ANALYSIS
    • 20.4.3 COMPANY SHARE ANALYSIS
    • 20.4.4 GEOGRAPHICAL PRESENCE
    • 20.4.5 PRODUCT PORTFOLIO
    • 20.4.6 RECENT DEVELOPMENT
  • 20.5 JOHNSON & JOHNSON SERVICES, INC.
    • 20.5.1 COMPANY SNAPSHOT
    • 20.5.2 REVENUE ANALYSIS
    • 20.5.3 COMPANY SHARE ANALYSIS
    • 20.5.4 GEOGRAPHICAL PRESENCE
    • 20.5.5 PRODUCT PORTFOLIO
    • 20.5.6 RECENT DEVELOPMENTS
  • 20.6 AKORN, INCORPORATED
    • 20.6.1 COMPANY OVERVIEW
    • 20.6.2 REVENUE ANALYSIS
    • 20.6.3 GEOGRAPHICAL PRESENCE
    • 20.6.4 PRODUCT PORTFOLIO
    • 20.6.5 RECENT DEVELOPMENT
  • 20.7 ALCON INC
    • 20.7.1 COMPANY SNAPSHOT
    • 20.7.2 REVENUE ANALYSIS
    • 20.7.3 GEOGRAPHICAL PRESENCE
    • 20.7.4 PRODUCT PORTFOLIO
    • 20.7.5 RECENT DEVELOPMENT
  • 20.8 ALEMBIC PHARMACEUTICALS LIMITED
    • 20.8.1 COMPANY SNAPSHOT
    • 20.8.2 REVENUE ANALYSIS
    • 20.8.3 GEOGRAPHICAL PRESENCE
    • 20.8.4 PRODUCT PORTFOLIO
    • 20.8.5 RECENT DEVELOPMENTS
  • 20.9 CARDINAL HEALTH
    • 20.9.1 COMPANY SNAPSHOT
    • 20.9.2 REVENUE ANALYSIS
    • 20.9.3 GEOGRAPHICAL PRESENCE
    • 20.9.4 PRODUCT PORTFOLIO
    • 20.9.5 RECENT DEVELOPMENTS
  • 20.10 CIPLA INC
    • 20.10.1 COMPANY SNAPSHOT
    • 20.10.2 REVENUE ANALYSIS
    • 20.10.3 GEOGRAPHICAL PRESENCE
    • 20.10.4 PRODUCT PORTFOLIO
    • 20.10.5 RECENT DEVELOPMENTS
  • 20.11 HORUS PHARMA
    • 20.11.1 COMPANY OVERVIEW
    • 20.11.2 GEOGRAPHICAL PRESENCE
    • 20.11.3 PRODUCT PORTFOLIO
    • 20.11.4 RECENT DEVELOPMENT
  • 20.12 HUBRX
    • 20.12.1 COMPANY SNAPSHOT
    • 20.12.2 PRODUCT PORTFOLIO
    • 20.12.3 RECENT DEVELOPMENTS
  • 20.13 NOVALIQ GMBH
    • 20.13.1 COMPANY OVERVIEW
    • 20.13.2 GEOGRAPHICAL PRESENCE
    • 20.13.3 PRODUCT PORTFOLIO
    • 20.13.4 RECENT DEVELOPMENT
  • 20.14 PERRIGO COMPANY PLC
    • 20.14.1 COMPANY SNAPSHOT
    • 20.14.2 REVENUE ANALYSIS
    • 20.14.3 GEOGRAPHICAL PRESENCE
    • 20.14.4 PRODUCT PORTFOLIO
    • 20.14.5 RECENT DEVELOPMENT
  • 20.15 PRESTIGE CONSUMER HEALTHCARE, INC.
    • 20.15.1 COMPANY SNAPSHOT
    • 20.15.2 REVENUE ANALYSIS
    • 20.15.3 PRODUCT PORTFOLIO
    • 20.15.4 RECENT DEVELOPMENTS
  • 20.16 ROHTO PHARMACEUTICAL CO., LTD.
    • 20.16.1 COMPANY SNAPSHOT
    • 20.16.2 REVENUE ANALYSIS
    • 20.16.3 GEOGRAPHICAL PRESENCE
    • 20.16.4 PRODUCT PORTFOLIO
    • 20.16.5 RECENT DEVELOPMENT
  • 20.17 SENJU PHARMACEUTICAL CO. LTD.
    • 20.17.1 COMPANY OVERVIEW
    • 20.17.2 REVENUE ANALYSIS
    • 20.17.3 GEOGRAPHICAL PRESENCE
    • 20.17.4 PRODUCT PORTFOLIO
    • 20.17.5 RECENT DEVELOPMENT
  • 20.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
    • 20.18.1 COMPANY SNAPSHOT
    • 20.18.2 REVENUE ANALYSIS
    • 20.18.3 GEOGRAPHICAL PRESENCE
    • 20.18.4 PRODUCT PORTFOLIO
  • 20.19 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 20.19.1 COMPANY SNAPSHOT
    • 20.19.2 REVENUE ANALYSIS
    • 20.19.3 GEOGRAPHICAL PRESENCE
    • 20.19.4 PRODUCT PORTFOLIO
    • 20.19.5 RECENT DEVELOPMENT
    • 20.19.6 RECENT DEVELOPMENTS
  • 20.20 VISUFARMA
    • 20.20.1 COMPANY OVERVIEW
    • 20.20.2 GEOGRAPHICAL PRESENCE
    • 20.20.3 PRODUCT PORTFOLIO
    • 20.20.4 RECENT DEVELOPMENTS

21 REFERENCES

222222 QUESTIONNAIRE

23 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 AGEING WORLD POPULATION
  • TABLE 2 EUROPE DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 3 EUROPE TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 4 EUROPE DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 5 EUROPE DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2016-2026 (USD MILLION)
  • TABLE 6 EUROPE LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2016-2026 (USD MILLION)
  • TABLE 7 EUROPE LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2016-2026 (USD MILLION)
  • TABLE 8 EUROPE SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2016-2026 (USD MILLION)
  • TABLE 9 EUROPE DIGITAL IN DRY EYE SYNDROME MARKET, BY PROCEDURE, 2017-2026 (USD MILLION)
  • TABLE 10 EUROPE OTHERS IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 11 EUROPE DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 12 EUROPE ANTI-INFLAMMATORY IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 13 EUROPE LUBRICATING AGENT IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 14 EUROPE ANTI-INFECTIVE IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 15 EUROPE ANTI-ALLERGIC IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 16 EUROPE CHOLINERGIC IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 17 EUROPE OTHERS IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 18 EUROPE DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 19 EUROPE MULTI DOSE IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20 EUROPE UNIT DOSE IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 21 EUROPE DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 22 EUROPE PRESCRIPTION (RX) DRUGS IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 23 EUROPE OVER THE COUNTER (OTC) DRUGS IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 24 EUROPE DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 25 EUROPE UNIT DOSE VIALS IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 26 EUROPE BOTTLES IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 27 EUROPE TUBES IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 28 EUROPE DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 29 EUROPE PLASTIC IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 30 EUROPE GLASS IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 31 EUROPE ALUMINUM IN DRY EYE SYNDROME MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 32 EUROPE DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 33 EUROPE GENERICS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 34 EUROPE BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 35 EUROPE BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 36 EUROPE DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 37 EUROPE HOME HEALTHCARE IN DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 38 EUROPE HOSPITALS IN DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 39 EUROPE CLINICS IN DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 40 EUROPE OTHERS IN DRY EYE SYNDROME MARKET, BY END USER, 2016-2026 (USD MILLION)
  • TABLE 41 EUROPE DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 42 EUROPE HOSPITAL PHARMACY IN DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 43 EUROPE RETAIL PHARMACY IN DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 44 EUROPE ONLINE PHARMACY IN DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 45 EUROPE OTHERS IN DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2016-2026 (USD MILLION)
  • TABLE 46 EUROPE DRY EYE SYNDROME MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 47 EUROPE DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 48 EUROPE TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 49 EUROPE DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 50 EUROPE LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 51 EUROPE SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 52 EUROPE DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 53 EUROPE DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 54 EUROPE DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 55 EUROPE DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 56 EUROPE DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 57 EUROPE DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 58 EUROPE BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 59 EUROPE DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 60 EUROPE DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 61 GERMANY DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 62 GERMANY TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 63 GERMANY DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 64 GERMANY LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 65 GERMANY SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 66 GERMANY DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 67 GERMANY DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 68 GERMANY DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 69 GERMANY DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 70 GERMANY DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 71 GERMANY DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 72 GERMANY BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 73 GERMANY DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 74 GERMANY DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 75 U.K. DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 76 U.K. TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 77 U.K. DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 78 U.K. LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 79 U.K. SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 80 U.K. DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 81 U.K. DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 82 U.K. DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 83 U.K. DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 84 U.K. DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 85 U.K. DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 86 U.K. BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 87 U.K. DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 88 U.K. DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 89 FRANCE DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 90 FRANCE TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 91 FRANCE DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 92 FRANCE LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 93 FRANCE SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 94 FRANCE DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 95 FRANCE DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 96 FRANCE DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 97 FRANCE DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 98 FRANCE DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 99 FRANCE DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 100 FRANCE BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 101 FRANCE DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 102 FRANCE DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 103 ITALY DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 104 ITALY TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 105 ITALY DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 106 ITALY LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 107 ITALY SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 108 ITALY DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 109 ITALY DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 110 ITALY DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 111 ITALY DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 112 ITALY DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 113 ITALY DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 114 ITALY BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 115 ITALY DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 116 ITALY DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 117 SPAIN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 118 SPAIN TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 119 SPAIN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 120 SPAIN LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 121 SPAIN SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 122 SPAIN DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 123 SPAIN DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 124 SPAIN DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 125 SPAIN DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 126 SPAIN DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 127 SPAIN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 128 SPAIN BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 129 SPAIN DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 130 SPAIN DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 131 RUSSIA DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 132 RUSSIA TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 133 RUSSIA DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 134 RUSSIA LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 135 RUSSIA SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 136 RUSSIA DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 137 RUSSIA DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 138 RUSSIA DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 139 RUSSIA DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 140 RUSSIA DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 141 RUSSIA DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 142 RUSSIA BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 143 RUSSIA DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 144 RUSSIA DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 145 NETHERLANDS DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 146 NETHERLANDS TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 147 NETHERLANDS DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 148 NETHERLANDS LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 149 NETHERLANDS SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 150 NETHERLANDS DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 151 NETHERLANDS DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 152 NETHERLANDS DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 153 NETHERLANDS DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 154 NETHERLANDS DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 155 NETHERLANDS DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 156 NETHERLANDS BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 157 NETHERLANDS DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 158 NETHERLANDS DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 159 SWITZERLAND DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 160 SWITZERLAND TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 161 SWITZERLAND DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 162 SWITZERLAND LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 163 SWITZERLAND SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 164 SWITZERLAND DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 165 SWITZERLAND DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 166 SWITZERLAND DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 167 SWITZERLAND DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 168 SWITZERLAND DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 169 SWITZERLAND DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 170 SWITZERLAND BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 171 SWITZERLAND DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 172 SWITZERLAND DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 173 BELGIUM DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 174 BELGIUM TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 175 BELGIUM DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 176 BELGIUM LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 177 BELGIUM SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 178 BELGIUM DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 179 BELGIUM DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 180 BELGIUM DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 181 BELGIUM DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 182 BELGIUM DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 183 BELGIUM DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 184 BELGIUM BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 185 BELGIUM DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 186 BELGIUM DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 187 TURKEY DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 188 TURKEY TEAR STIMULATORS IN DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)
  • TABLE 189 TURKEY DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 190 TURKEY LIQUID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 191 TURKEY SEMI SOLID IN DRY EYE SYNDROME MARKET, BY DOSAGE TYPE, 2017-2026 (USD MILLION)
  • TABLE 192 TURKEY DRY EYE SYNDROME MARKET, BY DRUG CLASS, 2017-2026 (USD MILLION)
  • TABLE 193 TURKEY DRY EYE SYNDROME MARKET, BY DOSE, 2017-2026 (USD MILLION)
  • TABLE 194 TURKEY DRY EYE SYNDROME MARKET, BY MEDICATION TYPE, 2017-2026 (USD MILLION)
  • TABLE 195 TURKEY DRY EYE SYNDROME MARKET, BY CONTAINER TYPE, 2017-2026 (USD MILLION)
  • TABLE 196 TURKEY DRY EYE SYNDROME MARKET, BY PACKAGING TYPE, 2017-2026 (USD MILLION)
  • TABLE 197 TURKEY DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 198 TURKEY BRANDS IN DRY EYE SYNDROME MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 199 TURKEY DRY EYE SYNDROME MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 200 TURKEY DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2017-2026 (USD MILLION)
  • TABLE 201 REST OF EUROPE DRY EYE SYNDROME MARKET, BY PRODUCT TYPE, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 EUROPE DRY EYE SYNDROME MARKET
  • FIGURE 2 EUROPE DRY EYE SYNDROME MARKET: DATA VALIDATION MODEL
  • FIGURE 3 EUROPE DRY EYE SYNDROME MARKET: DROC ANALYSIS
  • FIGURE 4 EUROPE DRY EYE SYNDROME MARKET: EUROPE VS REGIONAL
  • FIGURE 5 EUROPE DRY EYE SYNDROME MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 EUROPE DRY EYE SYNDROME MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 EUROPE DRY EYE SYNDROME MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 EUROPE DRY EYE SYNDROME MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 9 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF EUROPE DRY EYE SYNDROME MARKET
  • FIGURE 10 EUROPE IS ANTICIPATED TO DOMINATE THE EUROPE DRY EYE SYNDROME MARKET AND IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2019 TO 2026
  • FIGURE 11 INCREASING PREVALENCE OF DRY EYE DISEASES AND CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET ARE EXPECTED TO DRIVE THE EUROPE DRY EYE SYNDROME MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 12 TEAR STIMULATORE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE DRY EYE SYNDROME MARKET IN 2019 & 2026
  • FIGURE 13 EUROPE DRY EYE SYNDROME MARKET: BY PRODUCT TYPE, 2018
  • FIGURE 14 EUROPE DRY EYE SYNDROME MARKET: BY DOSAGE TYPE, 2018
  • FIGURE 15 EUROPE DRY EYE SYNDROME MARKET: BY DRUG CLASS, 2018
  • FIGURE 16 EUROPE DRY EYE SYNDROME MARKET: BY DOSE, 2018
  • FIGURE 17 EUROPE DRY EYE SYNDROME MARKET: BY MEDICATION TYPE, 2018
  • FIGURE 18 EUROPE DRY EYE SYNDROME MARKET: BY CONTAINER TYPE, 2018
  • FIGURE 19 EUROPE DRY EYE SYNDROME MARKET: BY PACKAGING TYPE, 2018
  • FIGURE 20 EUROPE DRY EYE SYNDROME MARKET: BY TYPE, 2018
  • FIGURE 21 EUROPE DRY EYE SYNDROME MARKET: BY END-USER, 2018
  • FIGURE 22 EUROPE DRY EYE SYNDROME MARKET: BYDISTRIBUTION CHANNEL, 2018
  • FIGURE 23 EUROPE DRY EYE SYNDROME MARKET SNAPSHOT (2018)
  • FIGURE 24 EUROPE DRY EYE SYNDROME MARKET: BY COUNTRY(2018)
  • FIGURE 25 EUROPE DRY EYE SYNDROME MARKET: BY COUNTRY(2019)
  • FIGURE 26 EUROPE DRY EYE SYNDROME MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 27 EUROPE DRY EYE SYNDROME MARKET: BY PRODUCTS & SERVICES (2019 - 2026)
  • FIGURE 28 EUROPE DRY EYE SYNDROME MARKET: COMPANY SHARE 2018 (%)
Back to Top